GTx to Present at the UBS Global Life Sciences Conference

GTx Presents Bone Turnover Marker Data and Additional PSA Progression Safety Analysis for Toremifene 80 mg Phase III ADT Clinical Trial

GTx to Present Additional Efficacy and Safety Analyses from the Toremifene 80 mg Phase III ADT Clinical Trial at the Annual Meeting of the American Society for Bone and Mineral Research

GTx Announces Webcast of Corporate Presentation at the NewsMakers in the Biotech Industry Conference

GTx, Inc. Reports Second Quarter 2008 Financial Results

GTx Announces Phase III Clinical Development of Toremifene 20 mg on Course Following Planned Safety Review

GTx, Inc. Announces Second Quarter 2008 Financial Results Conference Call and Webcast

GTx Announces Webcast of Corporate Presentation at Goldman Sachs 29th Annual Global Healthcare Conference

GTx Announces Phase III PIN Clinical Trial Will Continue As Planned

GTx, Inc. Reports First Quarter 2008 Financial Results

GTx Appoints Kenneth S. Robinson, MD to the Board of Directors

GTx, Inc. Announces First Quarter 2008 Financial Results Conference Call and Webcast

First Fracture Prevention Study in Men Receiving ADT for Prostate Cancer Presented at AACR Annual Meeting

GTx Announces Upcoming Presentation of Toremifene Citrate 80 mg Phase III ADT Clinical Trial Results